Chylomicronaemia--current diagnosis and future therapies

Area of Science:

• Metabolic Disorders
• Genetics
• Cardiovascular Disease

Background:

• Chylomicronaemia is a challenging metabolic disorder with unmet clinical needs.
• It presents as rare monogenic early-onset or common polygenic late-onset forms.
• Both forms are linked to increased pancreatitis risk; polygenic form may also increase cardiovascular disease risk.

Purpose of the Study:

• To review new developments in understanding chylomicronaemia.
• To discuss the genetic basis and clinical presentation of chylomicronaemia.
• To explore current and emerging treatment strategies.

Main Methods:

• Review of current literature on chylomicronaemia.
• Discussion of genetic mutations and contributing factors.
• Analysis of existing and novel therapeutic approaches.

Main Results:

• Monogenic chylomicronaemia involves mutations in LPL, APOC2, APOA5, LMF1, or GPIHBP1.
• Polygenic chylomicronaemia results from multiple genetic variants exacerbated by lifestyle and metabolic factors.
• Current treatments focus on dietary fat restriction and secondary factor control, with limited pharmacological efficacy.

Conclusions:

• Emerging therapies like LPL gene therapy, MTP and DGAT1 inhibition, and targeting apoC-III and ANGPTL3 show potential.
• Effective management requires understanding genetic underpinnings and addressing contributing factors.
• Further research into novel therapies is crucial for this challenging disorder.